<DOC>
	<DOCNO>NCT02678676</DOCNO>
	<brief_summary>The purpose study investigate mortality macrovascular morbidity well incidence malignancy time , high-risk diabetic participant previously receive long-term treatment either pioglitazone placebo combination usual medication glycaemic management .</brief_summary>
	<brief_title>An Observational Study Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone Placebo Addition Existing Antidiabetic Medications</brief_title>
	<detailed_description>This European , multicenter , observational study participant previously treat pioglitazone placebo addition exist anti diabetic medication . This 10-year observational study conduct follow-up PROactive study ( NCT00174993 ) investigate CV macrovascular effect observe pioglitazone time PROactive.In study , high risk T2DM patient previously enrol PROactive analyzed long-term incidence , nature , pattern malignancy pioglitazone placebo-treated groups.This study enrol 3599 participants.No treatment prescribe protocol participant manage accordance normal medical practice.The plan total duration study 10 year , data analyze report every 2 years.Participants assess nominal visit every 6 month every effort make obtain much require information possible .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Completion final visit PROactive Study ( NCT00174993 ) . Willingness ability give write informed consent observational study . There exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>